Please use this identifier to cite or link to this item: http://dspace.univ-temouchent.edu.dz/handle/123456789/4539
Full metadata record
DC FieldValueLanguage
dc.contributor.authorABDELLAOUI, KHADIDJA-
dc.date.accessioned2024-07-04T10:14:49Z-
dc.date.available2024-07-04T10:14:49Z-
dc.date.issued2024-
dc.identifier.urihttp://dspace.univ-temouchent.edu.dz/handle/123456789/4539-
dc.description.abstractThe pharmaceutical industry is one of the most important vital industries at the local and global levels due to its close link to human health. International companies have worked to protect their pharmaceutical innovations and inventions, especially undisclosed information, by controlling global markets for pharmaceutical products and achieving more profits, without taking into account the conditions and conditions of developing countries. Hence, comparative legislation has developed special protection for undisclosed information, including preventing others from violating these secrets and information using dishonest methods and practices through the lawsuit of unfair competition, and the TRIPS Agreement has also set out special rules for the protection of undisclosed information that is obligated to submit to government agencies and concerned authorities to obtain a license to market medicines.en_US
dc.publisherRUSSIAN LAW JOURNALen_US
dc.subjectundisclosed information; pharmaceutical industry; TRIPS Agreement; unfair competition lawsuit; criminal protection.en_US
dc.titleRULES FOR THE PROTECTION OF UNDISCLOSED INFORMATION AND ITS RELATIONSHIP TO THE PHARMACEUTICAL INDUSTRYen_US
Appears in Collections:Département Droit



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.